NIH award expands landmark Alzheimer’s biomarker study

Tuesday, September 13, 2016

The Alzheimer’s Disease Neuroimaging Initiative (ADNI)—the long-running NIH-supported study investigating brain and fluid biomarkers of the disease—enters a new phase of discovery with the launch of ADNI3. With the recent NIH award of approximately $40 million over the next five years—coupled with anticipated private sector contributions of $20 million through the Foundation for the National Institutes of Health (FNIH)—ADNI3 will use cutting-edge technologies in brain imaging as it recruits hundreds of new volunteers. Expansion of the groundbreaking study, now in its 12th year, will further develop ways to speed clinical trials by providing researchers the biomarkers needed to detect the onset and track the progression of Alzheimer’s disease.

[Read More]

GlobalMed named Arizona Bioscience Company of the Year

Thursday, September 8, 2016

The Arizona Bioindustry Association (AZBio) will honor GlobalMed as the Arizona Bioscience Company of the Year at the 2016 AZBio Awards on September 21, 2016. Hundreds of Arizona life science and business leaders as well as guests from across the country will be on hand at the Phoenix Convention Center to recognize GlobalMed for the many ways that the team, the company and their technology are making life better for people here in Arizona and around the world.

[Read More]

PureTech expands scientific advisory board team and advisory group

Friday, July 8, 2016

PureTech Health, a cross-disciplinary biotech company developing novel medicines at the interface of the gut, brain and immune system, has announced the appointment of Feng Zhang, Ph.D., to its scientific advisory board (SAB). The company has also appointed Jeff Stevens, as vice president of Growth Strategy & Operations and has expanded its team of senior advisors to include Meghan Fitzgerald, DrPH, executive vice president of Corporate Strategy, M&A and Health Policy at Cardinal Health; Atul Pande, M.D., former senior vice president and head of Neurosciences at GlaxoSmithKline; and Philip J. Larsen, M.D., Ph.D., global head of Diabetes Research & Development at Sanofi.

[Read More]